
Shares of telehealth firm Hims & Hers HIMS.N fall 19.22% to $41.45 premarket
Co says may no longer be able to sell compounded versions of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy, after US FDA removes it from shortage list
Adds the move could lead to customers cancelling their subscriptions, affecting revenue
Shares have risen 5 fold in the last 12 months